<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="66259">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02243293</url>
  </required_header>
  <id_info>
    <org_study_id>M14-868</org_study_id>
    <secondary_id>2014-002927-90</secondary_id>
    <nct_id>NCT02243293</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection</brief_title>
  <official_title>A Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection (SURVEYOR-II)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of ABT-493 and ABT-530 (or
      ABT-493/ABT-530) coadministered with and without ribavirin in adults with chronic HCV
      genotypes 2, 3, 4, 5 or 6 infection.

      In part 4, the primary objectives also include to assess the efficacy (SVR12) of treatment
      with ABT-493/ABT-530 combination regimen in GT2-infected DAA-naive subjects without
      cirrhosis compared to historical SVR12 rate of treatment with sofosbuvir plus RBV in
      GT2-infected DAA-naive subjects without cirrhosis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Actual">February 2017</completion_date>
  <primary_completion_date type="Actual">February 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of subjects who achieve 12-week sustained virologic response (SVR12) in each treatment arm</measure>
    <time_frame>12 weeks after last dose of study drug</time_frame>
    <description>Hepatitis C virus ribonucleic acid less than the lower limit of quantification</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of genotype 2 (GT2) subjects, in Part 4, treated with ABT-493/ABT-530 who achieve sustain virologic response 12 weeks after treatment (SVR12): Non-inferiority to historical control</measure>
    <time_frame>12 weeks after the last dose of study drug</time_frame>
    <description>Hepatitis C virus ribonucleic acid less than the lower limit of quantification</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects who achieve 4-week sustained virologic response (SVR4) in each treatment arm</measure>
    <time_frame>4 weeks after last dose of study drug</time_frame>
    <description>Hepatitis C virus ribonucleic acid less than the lower limit of quantification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with virologic failure during treatment</measure>
    <time_frame>Up to Treatment Week 12</time_frame>
    <description>Percentage of subjects with quantifiable hepatitis C virus ribonucleic acid at the end of treatment with at least 6 weeks of treatment, confirmed quantifiable hepatitis C virus ribonucleic acid after previously having unquantifiable hepatitis C virus ribonucleic acid, or a confirmed increase of at least one log10 in hepatitis C</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with Post-Treatment relapse</measure>
    <time_frame>12 weeks after the last dose of study drug</time_frame>
    <description>Percentage of subjects with confirmed quantifiable hepatitis C virus ribonucleic acid among subjects with unquantifiable hepatitis C virus ribonucleic acid at the end of treatment</description>
  </secondary_outcome>
  <number_of_arms>19</number_of_arms>
  <enrollment type="Actual">694</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <condition>Hepatitis C Virus</condition>
  <arm_group>
    <arm_group_label>ABT-493 Dose A + ABT-530 Dose A in HCV GT2-infected (12 weeks)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT-493 Dose A + ABT-530 Dose A for 12 weeks in HCV genotype 2 (GT2) -infected subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABT-493 Dose B + ABT-530 Dose A in HCV GT2-infected (12 weeks)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT-493 Dose B + ABT-530 Dose A for 12 weeks in HCV GT2-infected subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABT-493 + ABT-530 + RBV in HCV GT2-infected (12 weeks)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT-493 Dose B + ABT-530 Dose A coadministered with ribavirin (RBV) for 12 weeks in HCV GT2-infected subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABT-493 Dose A + ABT-530 Dose A in HCV GT3-infected (12 weeks)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT-493 Dose A + ABT-530 Dose A for 12 weeks in HCV genotype 3 (GT3) -infected subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABT-493 Dose B + ABT-530 Dose A in HCV GT3-infected (12 weeks)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT-493 Dose B + ABT-530 Dose A for 12 weeks in HCV GT3-infected subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABT-493 + ABT-530 + RBV in HCV GT3-infected (12 weeks)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT-493 Dose B + ABT-530 Dose A coadministered with ribavirin (RBV) for 12 weeks in HCV GT3-infected subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABT-493 Dose B + ABT-530 Dose B in HCV GT3-infected (12 weeks)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT-493 Dose B + ABT-530 Dose B for 12 weeks in HCV GT3-infected subjects.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABT-493 Dose B + ABT-530 Dose A in HCV GT2-infected (8 weeks)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT-493 Dose B + ABT-530 Dose A for 8 weeks in HCV GT2-infected subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABT-493 Dose B + ABT-530 Dose B in HCV GT2-infected (8 weeks)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT-493 Dose B + ABT-530 Dose B for 8 weeks in HCV GT2-infected subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABT-493 Dose A + ABT-530 Dose A in HCV GT2-infected (8 weeks)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT-493 Dose A + ABT-530 Dose A for 8 weeks in HCV GT2-infected subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABT-493 Dose B + ABT-530 Dose A in HCV GT3-infected (8 weeks)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT-493 Dose B + ABT-530 Dose A for 8 weeks in HCV GT3-infected subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABT-493 Dose A + ABT-530 Dose A in HCV GT3-infected (8 weeks)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT-493 Dose A + ABT-530 Dose A for 8 weeks in HCV GT3-infected subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABT-493 Dose B + ABT-530 Dose C in HCV GT3 cirrhotics (12 wks)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT-493 Dose B + ABT-530 Dose C for 12 weeks in HCV GT3-infected subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABT-493 Dose B + ABT-530 Dose C + RBV, GT3 cirrhotics (12 wks)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT-493 Dose B + ABT-530 Dose C + RBV for 12 weeks in HCV GT3-infected subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABT-493 Dose A + ABT-530 Dose A in HCV GT3 cirrhotics (12 wks)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT-493 Dose A + ABT-530 Dose A for 12 weeks in HCV GT3 cirrhotic subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABT-493 Dose A + ABT-530 Dose A + RBV, GT3 cirrhotics (12 wks)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT-493 Dose A + ABT-530 Dose A + RBV for 12 weeks in HCV GT3 cirrhotic subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABT-493/ABT-530, GT3-infected (12 wks)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT-493/ABT-530 in HCV GT3-infected subjects for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABT-493/ABT-530, GT3-infected (16 wks)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT-493/ABT-530 in HCV GT3-infected subjects for 16 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABT-493/ABT-530, GT2, 4, 5, or 6-infected (8 wks)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT-493/ABT-530 in HCV GT2, 4, 5, or 6-infected subjects for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-493</intervention_name>
    <description>Tablet</description>
    <arm_group_label>ABT-493 Dose A + ABT-530 Dose A in HCV GT2-infected (12 weeks)</arm_group_label>
    <arm_group_label>ABT-493 Dose B + ABT-530 Dose A in HCV GT2-infected (12 weeks)</arm_group_label>
    <arm_group_label>ABT-493 + ABT-530 + RBV in HCV GT2-infected (12 weeks)</arm_group_label>
    <arm_group_label>ABT-493 Dose A + ABT-530 Dose A in HCV GT3-infected (12 weeks)</arm_group_label>
    <arm_group_label>ABT-493 Dose B + ABT-530 Dose A in HCV GT3-infected (12 weeks)</arm_group_label>
    <arm_group_label>ABT-493 + ABT-530 + RBV in HCV GT3-infected (12 weeks)</arm_group_label>
    <arm_group_label>ABT-493 Dose B + ABT-530 Dose B in HCV GT3-infected (12 weeks)</arm_group_label>
    <arm_group_label>ABT-493 Dose B + ABT-530 Dose A in HCV GT2-infected (8 weeks)</arm_group_label>
    <arm_group_label>ABT-493 Dose B + ABT-530 Dose B in HCV GT2-infected (8 weeks)</arm_group_label>
    <arm_group_label>ABT-493 Dose A + ABT-530 Dose A in HCV GT2-infected (8 weeks)</arm_group_label>
    <arm_group_label>ABT-493 Dose B + ABT-530 Dose A in HCV GT3-infected (8 weeks)</arm_group_label>
    <arm_group_label>ABT-493 Dose A + ABT-530 Dose A in HCV GT3-infected (8 weeks)</arm_group_label>
    <arm_group_label>ABT-493 Dose B + ABT-530 Dose C in HCV GT3 cirrhotics (12 wks)</arm_group_label>
    <arm_group_label>ABT-493 Dose B + ABT-530 Dose C + RBV, GT3 cirrhotics (12 wks)</arm_group_label>
    <arm_group_label>ABT-493 Dose A + ABT-530 Dose A in HCV GT3 cirrhotics (12 wks)</arm_group_label>
    <arm_group_label>ABT-493 Dose A + ABT-530 Dose A + RBV, GT3 cirrhotics (12 wks)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-530</intervention_name>
    <description>Tablet</description>
    <arm_group_label>ABT-493 Dose A + ABT-530 Dose A in HCV GT2-infected (12 weeks)</arm_group_label>
    <arm_group_label>ABT-493 Dose B + ABT-530 Dose A in HCV GT2-infected (12 weeks)</arm_group_label>
    <arm_group_label>ABT-493 + ABT-530 + RBV in HCV GT2-infected (12 weeks)</arm_group_label>
    <arm_group_label>ABT-493 Dose A + ABT-530 Dose A in HCV GT3-infected (12 weeks)</arm_group_label>
    <arm_group_label>ABT-493 Dose B + ABT-530 Dose A in HCV GT3-infected (12 weeks)</arm_group_label>
    <arm_group_label>ABT-493 + ABT-530 + RBV in HCV GT3-infected (12 weeks)</arm_group_label>
    <arm_group_label>ABT-493 Dose B + ABT-530 Dose B in HCV GT3-infected (12 weeks)</arm_group_label>
    <arm_group_label>ABT-493 Dose B + ABT-530 Dose A in HCV GT2-infected (8 weeks)</arm_group_label>
    <arm_group_label>ABT-493 Dose B + ABT-530 Dose B in HCV GT2-infected (8 weeks)</arm_group_label>
    <arm_group_label>ABT-493 Dose A + ABT-530 Dose A in HCV GT2-infected (8 weeks)</arm_group_label>
    <arm_group_label>ABT-493 Dose B + ABT-530 Dose A in HCV GT3-infected (8 weeks)</arm_group_label>
    <arm_group_label>ABT-493 Dose A + ABT-530 Dose A in HCV GT3-infected (8 weeks)</arm_group_label>
    <arm_group_label>ABT-493 Dose B + ABT-530 Dose C in HCV GT3 cirrhotics (12 wks)</arm_group_label>
    <arm_group_label>ABT-493 Dose B + ABT-530 Dose C + RBV, GT3 cirrhotics (12 wks)</arm_group_label>
    <arm_group_label>ABT-493 Dose A + ABT-530 Dose A in HCV GT3 cirrhotics (12 wks)</arm_group_label>
    <arm_group_label>ABT-493 Dose A + ABT-530 Dose A + RBV, GT3 cirrhotics (12 wks)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin (RBV)</intervention_name>
    <description>Tablet</description>
    <arm_group_label>ABT-493 + ABT-530 + RBV in HCV GT2-infected (12 weeks)</arm_group_label>
    <arm_group_label>ABT-493 + ABT-530 + RBV in HCV GT3-infected (12 weeks)</arm_group_label>
    <arm_group_label>ABT-493 Dose B + ABT-530 Dose C + RBV, GT3 cirrhotics (12 wks)</arm_group_label>
    <arm_group_label>ABT-493 Dose A + ABT-530 Dose A + RBV, GT3 cirrhotics (12 wks)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-493/ABT-530</intervention_name>
    <description>Tablet</description>
    <arm_group_label>ABT-493/ABT-530, GT3-infected (12 wks)</arm_group_label>
    <arm_group_label>ABT-493/ABT-530, GT3-infected (16 wks)</arm_group_label>
    <arm_group_label>ABT-493/ABT-530, GT2, 4, 5, or 6-infected (8 wks)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female between at least 18 years of age at time of Screening

          -  Screening laboratory result indicating HCV Genotype 2, 3, 4, 5, or 6 infection.

          -  Chronic HCV infection.

          -  Subject must be either HCV treatment-naïve or treatment-experienced.

          -  Subject must be documented as non-cirrhotic or as having compensated cirrhosis (GT3
             only).

        Exclusion Criteria: - History of severe, life-threatening or other significant sensitivity
        to any drug.

          -  Female who is pregnant, planning to become pregnant during the study, or
             breastfeeding; or male whose partner is pregnant or planning to become pregnant
             during the study.

          -  Recent (within 6 months prior to study drug administration) history of drug or
             alcohol abuse that could preclude adherence to the protocol in the opinion of the
             investigator.

          -  Positive test result at Screening for hepatitis B surface antigen (HBsAg) or
             anti-human immunodeficiency virus antibody (HIV Ab).

          -  HCV genotype performed during screening indicating co-infection with more than one
             HCV genotype.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stanley Wang, MD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 132641</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 130743</name>
      <address>
        <city>Dothan</city>
        <state>Alabama</state>
        <zip>36305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 130755</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 130738</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 132612</name>
      <address>
        <city>Coronado</city>
        <state>California</state>
        <zip>92118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 132629</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 132633</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 130742</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 132602</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 132647</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 130752</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 130754</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 131530</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 130735</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 132601</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92161</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 130746</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 132600</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 130737</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 132627</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 132614</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 130741</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 132646</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 132609</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 132606</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 130745</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 132917</name>
      <address>
        <city>Bastrop</city>
        <state>Louisiana</state>
        <zip>71220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 130733</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 132918</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 130750</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 132631</name>
      <address>
        <city>Catonsville</city>
        <state>Maryland</state>
        <zip>21228</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 135352</name>
      <address>
        <city>Chevy Chase</city>
        <state>Maryland</state>
        <zip>20815</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 132610</name>
      <address>
        <city>Novi</city>
        <state>Michigan</state>
        <zip>48377</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 132639</name>
      <address>
        <city>St. Paul</city>
        <state>Minnesota</state>
        <zip>55114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 132607</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 132599</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 132604</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 132638</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 130734</name>
      <address>
        <city>Binghamton</city>
        <state>New York</state>
        <zip>13903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 138433</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 132628</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 132620</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 132611</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 132622</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 130739</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 132608</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 132625</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 132630</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 130749</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 132642</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02906</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 132649</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 132613</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 130740</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 132644</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 132648</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 131529</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 132603</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 132634</name>
      <address>
        <city>Newport News</city>
        <state>Virginia</state>
        <zip>23602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 132637</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 130887</name>
      <address>
        <city>Adelaide</city>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 136073</name>
      <address>
        <city>Brisbane</city>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 136049</name>
      <address>
        <city>Camperdown</city>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 136048</name>
      <address>
        <city>Clayton</city>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 130886</name>
      <address>
        <city>Darlinghurst</city>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 130882</name>
      <address>
        <city>Fitzroy, Melbourne</city>
        <zip>3065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 130881</name>
      <address>
        <city>Greenslopes</city>
        <zip>4120</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 130888</name>
      <address>
        <city>Kingswood</city>
        <zip>2747</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 136074</name>
      <address>
        <city>Melbourne</city>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 130884</name>
      <address>
        <city>Parkville</city>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 130880</name>
      <address>
        <city>Perth</city>
        <zip>6000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 130883</name>
      <address>
        <city>Westmead</city>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 130722</name>
      <address>
        <city>Calgary</city>
        <zip>T2N 4Z6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 130723</name>
      <address>
        <city>Edmonton, AB</city>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 130720</name>
      <address>
        <city>Montreal</city>
        <zip>H2X 2P4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 130721</name>
      <address>
        <city>Toronto</city>
        <zip>M9V 4B8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 130893</name>
      <address>
        <city>Nice, Cedex 3</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 130890</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 130910</name>
      <address>
        <city>Busan</city>
        <zip>602-739</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 136075</name>
      <address>
        <city>Christchurch, Canterbury</city>
        <zip>8011</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 130915</name>
      <address>
        <city>Dunedin</city>
        <zip>9016</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 130914</name>
      <address>
        <city>Grafton</city>
        <zip>1010</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 130917</name>
      <address>
        <city>Hamilton, Waikato</city>
        <zip>3204</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 130916</name>
      <address>
        <city>Wellington</city>
        <zip>6021</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 130928</name>
      <address>
        <city>Tainan, ROC</city>
        <zip>704</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 132405</name>
      <address>
        <city>Glasgow</city>
        <zip>G12 0YN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 130935</name>
      <address>
        <city>London</city>
        <zip>E1 1BB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 130932</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>France</country>
    <country>Korea, Republic of</country>
    <country>New Zealand</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Italy</country>
  </removed_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 8, 2017</lastchanged_date>
  <firstreceived_date>September 4, 2014</firstreceived_date>
  <firstreceived_results_disposition_date>February 8, 2017</firstreceived_results_disposition_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis C Virus</keyword>
  <keyword>Hepatitis C Genotype 4</keyword>
  <keyword>Hepatitis C</keyword>
  <keyword>HCV</keyword>
  <keyword>Hepatitis C Genotype 5</keyword>
  <keyword>interferon free</keyword>
  <keyword>Hepatitis C Genotype 2</keyword>
  <keyword>Hepatitis C Genotype 3</keyword>
  <keyword>Hepatitis C Genotype 6</keyword>
  <keyword>Chronic Hepatitis C</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ribavirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted -->
</clinical_study>
